A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.
The study measured phosphoproteome-wide changes in hematopoietic BaF3 cells in response to perturbation of several Src family kinases, identifying four SFK negative feedback mechanisms that appear to be suppressed in cell lines resistant to the drug.
Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.
The data covers how 3,800 different inhibitors affect 172 kinases. The researchers grouped the proteins based both on sequence and pharmacological relationships and by their interactions with various compound chemotypes.
The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.
The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.